| pubmed-article:6589165 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6589165 | lifeskim:mentions | umls-concept:C0025519 | lld:lifeskim |
| pubmed-article:6589165 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:6589165 | lifeskim:mentions | umls-concept:C0014582 | lld:lifeskim |
| pubmed-article:6589165 | lifeskim:mentions | umls-concept:C1880989 | lld:lifeskim |
| pubmed-article:6589165 | lifeskim:mentions | umls-concept:C0243071 | lld:lifeskim |
| pubmed-article:6589165 | lifeskim:mentions | umls-concept:C1710548 | lld:lifeskim |
| pubmed-article:6589165 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:6589165 | pubmed:dateCreated | 1984-9-19 | lld:pubmed |
| pubmed-article:6589165 | pubmed:abstractText | The metabolism of doxorubicin (A), 4'-epidoxorubicin (E) and 4'-deoxydoxorubicin (D) was studied in vitro by incubating the analogs with rat liver subcellular fractions and in vivo by chromatographic analysis of human urine. Metabolites were identified by high-pressure liquid chromatography, fluorescence spectroscopy and enzymatic conversion. Human urine contained unchanged drug as well as the corresponding alcohol metabolites in all cases; however, urine of patients who received E also contained two glucuronides which could not be detected in the urine of patients who received A or D. We have identified these glucuronides as 4'-epidoxorubicin glucuronide (E-Glu) and 4'-epidoxorubicinol glucuronide (Eol-Glu). It was concluded that the glucuronide moiety is linked to the daunosamine sugar at the C4'-OH position. A hypothesis is proposed that this glucuronidation pathway may explain the differences in pharmacokinetics and toxicity between E and A. Rat liver microsomes were found to convert all three drugs to the 7-deoxyaglycones at the same rate. Rat liver 100,000 g supernatant was found to be capable of converting these drugs to their respective alcohol metabolites, doxorubicinol (Aol) being formed somewhat slower than 4'-epidoxorubicinol (Eol) and 4'-deoxydoxorubicinol (Dol). | lld:pubmed |
| pubmed-article:6589165 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6589165 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6589165 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6589165 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6589165 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6589165 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6589165 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6589165 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6589165 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6589165 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6589165 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:6589165 | pubmed:issn | 0277-5379 | lld:pubmed |
| pubmed-article:6589165 | pubmed:author | pubmed-author:van MaanenJ... | lld:pubmed |
| pubmed-article:6589165 | pubmed:author | pubmed-author:PinedoH MHM | lld:pubmed |
| pubmed-article:6589165 | pubmed:author | pubmed-author:McVieJ GJG | lld:pubmed |
| pubmed-article:6589165 | pubmed:author | pubmed-author:WeenenHH | lld:pubmed |
| pubmed-article:6589165 | pubmed:author | pubmed-author:de PlanqueM... | lld:pubmed |
| pubmed-article:6589165 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6589165 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:6589165 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6589165 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6589165 | pubmed:pagination | 919-26 | lld:pubmed |
| pubmed-article:6589165 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:6589165 | pubmed:meshHeading | pubmed-meshheading:6589165-... | lld:pubmed |
| pubmed-article:6589165 | pubmed:meshHeading | pubmed-meshheading:6589165-... | lld:pubmed |
| pubmed-article:6589165 | pubmed:meshHeading | pubmed-meshheading:6589165-... | lld:pubmed |
| pubmed-article:6589165 | pubmed:meshHeading | pubmed-meshheading:6589165-... | lld:pubmed |
| pubmed-article:6589165 | pubmed:meshHeading | pubmed-meshheading:6589165-... | lld:pubmed |
| pubmed-article:6589165 | pubmed:meshHeading | pubmed-meshheading:6589165-... | lld:pubmed |
| pubmed-article:6589165 | pubmed:meshHeading | pubmed-meshheading:6589165-... | lld:pubmed |
| pubmed-article:6589165 | pubmed:meshHeading | pubmed-meshheading:6589165-... | lld:pubmed |
| pubmed-article:6589165 | pubmed:meshHeading | pubmed-meshheading:6589165-... | lld:pubmed |
| pubmed-article:6589165 | pubmed:meshHeading | pubmed-meshheading:6589165-... | lld:pubmed |
| pubmed-article:6589165 | pubmed:meshHeading | pubmed-meshheading:6589165-... | lld:pubmed |
| pubmed-article:6589165 | pubmed:meshHeading | pubmed-meshheading:6589165-... | lld:pubmed |
| pubmed-article:6589165 | pubmed:year | 1984 | lld:pubmed |
| pubmed-article:6589165 | pubmed:articleTitle | Metabolism of 4'-modified analogs of doxorubicin. unique glucuronidation pathway for 4'-epidoxorubicin. | lld:pubmed |
| pubmed-article:6589165 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6589165 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:6589165 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6589165 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6589165 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6589165 | lld:pubmed |
